Gosset Ownership
Private
Employees
~50
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Asha Therapeutics General Information
Asha Therapeutics has nominated two lead candidates—ASHA‑624 targeting SARM1 for ALS and related neuropathies, and ASHA‑091 for Alzheimer’s, Parkinson’s, and ALS. Both have shown robust efficacy in preclinical models. The company expects to initiate first-in-human clinical trials by late 2024 or early 2025. No active clinical trials are currently registered on ClinicalTrials.gov as of May 2025.
Contact Information
Primary Industry
Biotech
Corporate Office
Washington, District of Columbia
United States
United States
Drug Pipeline
ASHA-624
Pre-clinicalKey Partnerships
Johnson & Johnson Innovation – JLABS/BARDA through the BLUE KNIGHT™ program partnership for rapid response drug development initiatives.
Asha Therapeutics Funding
No funding data available
To view Asha Therapeutics's complete valuation and funding history, request access »